WO1994008624A3 - Procedes et compositions d'imagerie diagnostique et therapeutique - Google Patents

Procedes et compositions d'imagerie diagnostique et therapeutique Download PDF

Info

Publication number
WO1994008624A3
WO1994008624A3 PCT/US1993/009645 US9309645W WO9408624A3 WO 1994008624 A3 WO1994008624 A3 WO 1994008624A3 US 9309645 W US9309645 W US 9309645W WO 9408624 A3 WO9408624 A3 WO 9408624A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnostic imaging
methods
therapeutic
imaging compositions
polymer
Prior art date
Application number
PCT/US1993/009645
Other languages
English (en)
Other versions
WO1994008624A2 (fr
Inventor
Robert A. Snow
David L. Ladd
John L. Toner
Original Assignee
Sterling Winthrop Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc. filed Critical Sterling Winthrop Inc.
Priority to JP6510155A priority Critical patent/JPH08502300A/ja
Priority to DE69327659T priority patent/DE69327659T2/de
Priority to EP93923819A priority patent/EP0664713B1/fr
Priority to AU53550/94A priority patent/AU5355094A/en
Publication of WO1994008624A2 publication Critical patent/WO1994008624A2/fr
Publication of WO1994008624A3 publication Critical patent/WO1994008624A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des procédés et des compositions d'imagerie diagnostique et de thérapeutique. Un polymère comprend des unités qui contiennent une fraction poly(alkylène oxyde) liée au résidu d'un agent chélateur. Un agent cytotoxique est associé audit polymère.
PCT/US1993/009645 1992-10-14 1993-10-07 Procedes et compositions d'imagerie diagnostique et therapeutique WO1994008624A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP6510155A JPH08502300A (ja) 1992-10-14 1993-10-07 治療および診断像形成組成物および方法
DE69327659T DE69327659T2 (de) 1992-10-14 1993-10-07 Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
EP93923819A EP0664713B1 (fr) 1992-10-14 1993-10-07 Procedes et compositions d'imagerie diagnostique et therapeutique
AU53550/94A AU5355094A (en) 1992-10-14 1993-10-07 Therapeutic and diagnostic imaging compositions and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96074592A 1992-10-14 1992-10-14
US960,745 1992-10-14

Publications (2)

Publication Number Publication Date
WO1994008624A2 WO1994008624A2 (fr) 1994-04-28
WO1994008624A3 true WO1994008624A3 (fr) 1994-05-26

Family

ID=25503562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/009645 WO1994008624A2 (fr) 1992-10-14 1993-10-07 Procedes et compositions d'imagerie diagnostique et therapeutique

Country Status (8)

Country Link
US (1) US5932188A (fr)
EP (1) EP0664713B1 (fr)
JP (1) JPH08502300A (fr)
AU (1) AU5355094A (fr)
CA (1) CA2147151A1 (fr)
DE (1) DE69327659T2 (fr)
ES (1) ES2140469T3 (fr)
WO (1) WO1994008624A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
DE19505960A1 (de) 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
NZ331629A (en) * 1996-04-01 2000-04-28 Epix Medical Inc Bioactivated diagnostic imaging contrast agents
US20040170563A1 (en) * 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6896874B2 (en) * 1998-05-26 2005-05-24 Wisconsin Alumni Research Foundation MR-signal emitting coatings
US6361759B1 (en) * 1998-05-26 2002-03-26 Wisconsin Alumni Research Foundation MR signal-emitting coatings
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
JP3822479B2 (ja) 2001-10-10 2006-09-20 株式会社カネカ 還元型補酵素ｑ水溶液の安定化組成
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
US20040253292A1 (en) * 2003-04-23 2004-12-16 Wisconsin Alumni Research Foundation MR-signal emitting coatings
WO2005049096A2 (fr) * 2003-11-14 2005-06-02 Dow Global Technologies Inc. Chelateurs a retention sanguine amelioree
AU2005229001A1 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
EP1915620B1 (fr) * 2005-08-02 2010-06-02 Xbiotech Inc DIAGNOSTIC, TRAITEMENT ET PRÉVENTION DE TROUBLES VASCULAIRES AU MOYEN D'AUTO-ANTICORPS DIRIGÉS CONTRE L'IL-1alpha
US8457712B2 (en) * 2005-12-30 2013-06-04 Wisconsin Alumni Research Foundation Multi-mode medical device system and methods of manufacturing and using same
US20070156042A1 (en) * 2005-12-30 2007-07-05 Orhan Unal Medical device system and method for tracking and visualizing a medical device system under MR guidance
AR059193A1 (es) 2006-01-31 2008-03-12 Bayer Schering Pharma Ag Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
SI2109623T1 (sl) * 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
US8532742B2 (en) * 2006-11-15 2013-09-10 Wisconsin Alumni Research Foundation System and method for simultaneous 3DPR device tracking and imaging under MR-guidance for therapeutic endovascular interventions
CN101541857B (zh) * 2006-11-27 2012-12-12 阿克塔马克斯手术器材有限责任公司 多官能聚环氧烷、水凝胶和组织粘合剂
US20080183070A1 (en) * 2007-01-29 2008-07-31 Wisconsin Alumni Research Foundation Multi-mode medical device system with thermal ablation capability and methods of using same
US8412306B2 (en) * 2007-02-28 2013-04-02 Wisconsin Alumni Research Foundation Voltage standing wave suppression for MR-guided therapeutic interventions
EP2005970A1 (fr) 2007-06-22 2008-12-24 Berlin Science Partners GmbH i.V. Imagerie Diagnostique par combinaison de moyens de contraste
EP2072060A1 (fr) 2007-12-18 2009-06-24 Institut Curie Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines
WO2009108891A2 (fr) * 2008-02-29 2009-09-03 Egen, Inc. Poloxamères modifiés utilisés pour l’expression génique et méthodes associées
RU2498998C2 (ru) 2008-05-30 2013-11-20 ИксБиотеч, Инк. АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク，インコーポレイテッドＸｂｉｏｔｅｃｈ，Ｉｎｃ． 病原性単球の標的化
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
EP2608808B1 (fr) 2010-08-23 2017-01-18 XBiotech, Inc Traitement de maladies néoplasiques
ES2697056T3 (es) 2011-04-01 2019-01-21 Xbiotech Inc Tratamiento para patologías dermatológicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3582813A4 (fr) 2017-02-16 2020-12-30 XBiotech, Inc Traitement de l'hidradénite suppurative

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0277088A2 (fr) * 1987-01-19 1988-08-03 Schering Aktiengesellschaft Complexes de polymères, leur procédé de préparation et compositions pharmaceutiques les contenant
WO1991018630A1 (fr) * 1990-05-30 1991-12-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Agents anti-tumoraux substitues avec du polyether
EP0481526A1 (fr) * 1989-04-07 1992-04-22 Nycomed Salutar, Inc. Agents de chélation
WO1994001393A1 (fr) * 1992-07-03 1994-01-20 The Green Cross Corporation Nouveau chelateur, complexe compose dudit chelateur et d'un atome metallique, et agent diagnostique renfermant ledit complexe

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859337A (en) * 1969-06-11 1975-01-07 Stauffer Chemical Co Ethylenediaminetetraacetic acid anhydride derivatives
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
CS226911B1 (en) * 1981-10-28 1984-04-16 Jaroslav Kahovec Polymere polydonor komplexons and method of their manufacture polymere polydonor
US4423158A (en) * 1983-01-27 1983-12-27 Gelinnovation Handelsaktiebolag Ion adsorbent for metals having a coordination number greater than two
US4972837A (en) * 1983-04-26 1990-11-27 Regents Of The University Of California Contrast agents for nuclear magnetic resonance imaging
JPS59215321A (ja) * 1983-05-23 1984-12-05 Sumitomo Chem Co Ltd 二官能性配位子化合物を結合した反応性高分子
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
US4943523A (en) * 1984-01-30 1990-07-24 Enzo Biochem, Inc. Detectable molecules, method of preparation and use
US4602097A (en) * 1984-06-11 1986-07-22 Ulano Corporation Water soluble photoinitiator benzophenone and thioxanthenone ethoxy-ether derivatives
US4687658A (en) * 1984-10-04 1987-08-18 Salutar, Inc. Metal chelates of diethylenetriaminepentaacetic acid partial esters for NMR imaging
US4687659A (en) * 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US4859451A (en) * 1984-10-04 1989-08-22 Salutar, Inc. Paramagnetic contrast agents for MR imaging
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
US4826673A (en) * 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4980148A (en) * 1985-02-06 1990-12-25 Mallinckrodt, Inc. Methods for enhancing magnetic resonance imaging
US4746507A (en) * 1985-04-02 1988-05-24 Salutar, Inc. EDHPA based contrast agents for MR imaging, apparatus and methods
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
IT1213029B (it) * 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US4909257A (en) * 1986-05-01 1990-03-20 The Regents Of The University Of California Method for attaining in vivo tissue-specific contrast by nuclear magnetic resonance imaging
US4814098A (en) * 1986-09-06 1989-03-21 Bellex Corporation Magnetic material-physiologically active substance conjugate
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US5198208A (en) * 1987-07-16 1993-03-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
US5137711A (en) * 1988-07-19 1992-08-11 Mallickrodt Medical, Inc. Paramagnetic dtpa and edta alkoxyalkylamide complexes as mri agents
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5283339A (en) * 1988-11-23 1994-02-01 California Institute Of Technology Immobilized metal aqueous two-phase extraction and precipitation
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
SE465155B (sv) * 1989-12-19 1991-08-05 Exploaterings Ab Tbf Metallkelatbildande hydrofil polymer foer adsorption etc samt ett saett foer framstaellning av polymeren
DE4011684A1 (de) * 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
EP0693288B1 (fr) * 1990-04-10 1999-10-13 Imarx Pharmaceutical Corp. Polymères commes substances de contraste pour résonance magnétique
US5077037A (en) * 1990-08-03 1991-12-31 Mallinckrodt Medical, Inc. Novel compositions for magnetic resonance imaging
US5385719A (en) * 1991-09-24 1995-01-31 Unger; Evan C. Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0277088A2 (fr) * 1987-01-19 1988-08-03 Schering Aktiengesellschaft Complexes de polymères, leur procédé de préparation et compositions pharmaceutiques les contenant
EP0481526A1 (fr) * 1989-04-07 1992-04-22 Nycomed Salutar, Inc. Agents de chélation
WO1991018630A1 (fr) * 1990-05-30 1991-12-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Agents anti-tumoraux substitues avec du polyether
WO1994001393A1 (fr) * 1992-07-03 1994-01-20 The Green Cross Corporation Nouveau chelateur, complexe compose dudit chelateur et d'un atome metallique, et agent diagnostique renfermant ledit complexe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. CHIROL ET AL.: "RADIOLABELING OF NEW POLYMER CHELATES (PC)", JOURNAL OF NUCLEAR MEDECINE, vol. 31, no. 5, May 1990 (1990-05-01), NEW YORK US, pages 897 *

Also Published As

Publication number Publication date
JPH08502300A (ja) 1996-03-12
WO1994008624A2 (fr) 1994-04-28
CA2147151A1 (fr) 1994-04-28
DE69327659D1 (de) 2000-02-24
US5932188A (en) 1999-08-03
DE69327659T2 (de) 2000-09-21
ES2140469T3 (es) 2000-03-01
EP0664713B1 (fr) 2000-01-19
AU5355094A (en) 1994-05-09
EP0664713A1 (fr) 1995-08-02

Similar Documents

Publication Publication Date Title
WO1994008624A3 (fr) Procedes et compositions d'imagerie diagnostique et therapeutique
AU2832389A (en) Improved poly (propylene glycol fumarate) compositions for biomedical applications
IL107108A0 (en) Microcapsules,processes for the preparation thereof and contrast compositions containing the same
EP0841936A4 (fr) Compositions d'agents therapeutiques de conjugaison stabilises, formulation d'administration et de diagnostic les contenant
MXPA00004282A (es) Catalizadores mejorados de cianuro dimetalico que contienen polieter.
EP1310244A3 (fr) Compositions comprenant un agent anticancéreux et un bloc-copolymère polyether
NO903871D0 (no) Flytende polymer og polyolsammensetninger, og fremgangsmaate for fremstilling av fenolfunksjonell polymer.
WO1995022991A3 (fr) Copolymeres sequences
EP0665729A4 (fr) Polymeres biocompatibles contenant des fractions therapeutiques ou de diagnostic.
EP0575123A3 (fr) Composition d'un copolymère d'éthylène.
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
CA2011171A1 (fr) Poly(esters phosphoriques) biodegradables
IL106665A0 (en) Powder compositions for inhalation
NZ240838A (en) N,o-sulphated heparosans, preparation using e.coli and pharmaceutical compositions thereof
CA2172616A1 (fr) Tropyl 7-azaindol-3-ylcarboxamides, antitussifs
EP0620256A3 (fr) Composition polymérique pour le traitement hydrophile.
WO1996021468A3 (fr) Interferent chimiquement modifie
EG19136A (en) Polymer compositions.
CA2264063A1 (fr) Composes de cryptophycine
FR2684390B1 (fr) Elimination de couches d'oxyde de moulages en titane, par utilisation d'un agent de desoxydation alcalino-terreux.
IL110460A0 (en) Bis-naphthalimides and pharmaceutical compositions containing them
IL108624A0 (en) Pseudopeptides, their preparation and pharmaceutical compositions containing them
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
CA2330424A1 (fr) Methode amelioree d'eradication d'helicobacter pylori
ZA918381B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CZ FI HU JP KR NO RU SK UA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CZ FI HU JP KR NO RU SK UA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2147151

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993923819

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993923819

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993923819

Country of ref document: EP